Share Name Share Symbol Market Type Share ISIN Share Description
Immunovia Ab (publ) LSE:0G8X London Ordinary Share SE0006091997 IMMUNOVIA ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 191.40 0.00 0.00 0.00 0.00 0.00 70 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
- - - - 0

Change in the Number of Shares and Votes in Immunovia AB (publ)

30/06/2020 8:18am

PR Newswire (US)

Immunovia Ab (publ) (LSE:0G8X)
Historical Stock Chart

From Jun 2020 to Aug 2020

Click Here for more Immunovia Ab (publ) Charts.

LUND, Sweden, June 30, 2020 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia") today announced that the number of shares and votes in Immunovia has changed due to the fact that shares have been registered after the directed share issue which was carried out in June 2020.

Through the registration of shares after the new issue, the number of outstanding shares and votes increases by 2,948,228 from 19,654,853 to 22,603,081. The share capital increases by SEK 147,411.40 from SEK 982,742.65 to SEK 1,130 154.05.

This is information that Immunovia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 09:00 CET on June 30, 2020.

About Immunovia

Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia's proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique "disease biomarker signature".

The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.

The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world's largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently entering the final validation for sales start Q4 2020. When validated, IMMray™ PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome.

Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and Lund, Sweden will provide laboratory testing services in two accredited reference laboratories.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit

For more information, please contact:
Julie Silber
Director of Investor Relations, Immunovia
Tel: +46-7-93-486-277

This information was brought to you by Cision,c3144609

The following files are available for download:


Copyright 2020 PR Newswire

1 Year Immunovia Ab (publ) Chart

1 Year Immunovia Ab (publ) Chart

1 Month Immunovia Ab (publ) Chart

1 Month Immunovia Ab (publ) Chart
ADVFN Advertorial
Your Recent History
Immunovia ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200808 01:07:25